Wanxiwei (Pazopanib) 200mg*30 | Loncom China Generic | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: Wanxiwei (Pazopanib) 200mg — China-Mainland

Wanxiwei (万希维) is a Chinese generic of pazopanib manufactured by Shandong Loncom Pharmaceutical Co., Ltd., a Chinese pharmaceutical company. It is supplied as 200 mg tablets (0.2 g) in 30-tablet packs. Wanxiwei is one of the domestically approved pazopanib generics that provide an affordable, bioequivalent alternative to the originator Votrient for renal cell carcinoma and soft tissue sarcoma.

Chinese generic pazopanib has been included in China's national medical insurance scheme for the renal cell carcinoma indication, and domestic generics are priced well below the imported originator. For buyers seeking a cost-effective route to pazopanib, Wanxiwei offers the same active ingredient and dosing as the branded product.

What Is Wanxiwei Used For?

Wanxiwei treats advanced renal cell carcinoma (RCC) in the first-line setting and after prior cytokine therapy, and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. It delivers the same anti-angiogenic therapy as the originator pazopanib.

How Does Wanxiwei Work?

Pazopanib, the active ingredient in Wanxiwei, is a multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β) and c-Kit. By inhibiting these kinases, Wanxiwei disrupts tumour angiogenesis, reducing the blood supply that growing tumours depend on and slowing their progression.

Indications

  • Advanced renal cell carcinoma (RCC), first-line and after prior cytokine therapy.
  • Advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.

Dosage and Administration

The recommended dose is 800 mg once daily, taken as four 200 mg tablets on an empty stomach (at least 1 hour before or 2 hours after a meal), swallowed whole. A 30-tablet pack provides about one week of therapy. Dose adjustment is required for hepatic impairment, and liver function and blood pressure are monitored during treatment.

Side Effects

Common adverse reactions include diarrhoea, hypertension, hair colour changes, nausea, fatigue, decreased appetite and vomiting. Pazopanib carries a boxed warning for severe hepatotoxicity, requiring liver function monitoring before and during therapy. Hypothyroidism, haemorrhage and QT prolongation may occur, and patients should report yellowing, unusual bleeding or palpitations.

Storage

Store Wanxiwei below 30°C in the original pack, away from moisture and out of the reach of children. Use before the expiry date printed on the pack.

Why Choose the GLT?

GLT sources Wanxiwei through a documented China supply chain and confirms each batch against the manufacturer's details. Chinese generic pazopanib is typically priced at a small fraction of the branded originator's US list price, making long-term anti-angiogenic therapy far more sustainable. We provide clear purchase documentation and direct contact for ongoing support.

How to Order Wanxiwei from GLT

To order Wanxiwei 200 mg (30 tablets), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and order type, and we confirm batch details and lead time before dispatch.

FAQ

Is Wanxiwei the same as Votrient? Wanxiwei contains the same active ingredient (pazopanib) and is bioequivalent to Votrient; it is a Chinese generic by Shandong Loncom.

What is the standard dose? 800 mg once daily (four 200 mg tablets), taken on an empty stomach.

Where can I order Wanxiwei? GLT can supply Wanxiwei internationally; contact us on WhatsApp or email for availability.

Related Oncology Products

Mounjaro KwikPen (Tirzepatide) 10–60mg/2.4mL Multi-Dose | Eli Lilly USA | GLT

Mounjaro KwikPen — Eli Lilly single-patient multi-dose pen, six US strengths (10–60mg/2.4mL, 4 doses each)...

SPINRAZA (Nusinersen) 12mg/5mL | Buy from China | SMA Therapy | GLT

Biogen's first-in-class antisense oligonucleotide for SMA, NMPA-approved and nationally reimbursed in China — buy from...

Avabopa (Avatrombopag) 20mg*30 Tablets | Tongmeng TLPH Laos | GLT

Avabopa — avatrombopag 20mg by Tongmeng (Lao) Pharmaceutical and Food Co., Ltd. (TLPH), Lao Reg....

Olumiant (Baricitinib) 2mg/4mg Tablets | JAK1/JAK2 Inhibitor | Eli Lilly USA | GLT

Eli Lilly's selective JAK1/JAK2 inhibitor for rheumatoid arthritis, atopic dermatitis and severe alopecia areata.

Tirzema (Tirzepatide) 2.5/5/7.5mg/0.5mL Single-Dose Pen | Incepta Bangladesh | GLT

Tirzema — Incepta Pharmaceuticals tirzepatide single-dose pen, three official strengths (2.5/5/7.5mg/0.5mL) for T2DM and weight...

KangQuXin 康曲欣 (Avatrombopag) 20mg*10 Tablets | Beijing Continent Gyre | GLT

KangQuXin — avatrombopag by Beijing Continent Pharmaceutical (Gyre Therapeutics, Nasdaq: GYRE), China Mainland

Baricent (Baricitinib) 2mg | Generic JAK1/JAK2 Inhibitor | Incepta Pharmaceuticals Ltd. | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Incepta Pharmaceuticals Ltd. (Bangladesh) — an affordable alternative to Olumiant...

AVATODX (Avatrombopag) 20mg*30 Tablets | Bigbear Pharmaceutical Laos | GLT

AVATODX — avatrombopag 20mg by Bigbear Pharmaceutical (Lao) Co., Ltd., Lao Reg. 06L0985/23, 30-tablet bottle